Research Associate, Invivo Pharmacology
Confirmed on the employer's own hiring board on Sep 24, 2026. First seen by Alion on Aug 7, 2026. Enveda Biosciences scores B on the Alion truth index.
Let’s build the future of medicine-together.
Research Associate , In Vivo Pharmacology
Hyderabad, India | Full-Time
YOUR ROLE
As a Research Associate in In Vivo Pharmacology at Enveda, you will be central to validating the biological activity of our novel chemical entities in living systems. Working side-by-side with discovery scientists and disease-area experts, you will establish and run in vivo disease models, generate translatable data, and help shape the pharmacological story of our drug programmes.
WHAT YOU'LL DO
Conduct in vivo efficacy studies for novel chemical entities across Enveda drug discovery programmes
Establish and validate in vivo disease models with physiologically relevant endpoints and translational biomarkers
Handle small animals; perform multi-route dosing, dissections, tissue harvesting, and downstream assays (ELISA, qPCR, Western Blot)
Perform statistically supported data analysis and deliver timely results to enable informed decision-making
Collaborate with discovery scientists, present data, and contribute creative ideas to advance drug discovery programmes
WHAT WE'RE LOOKING FOR
M.Pharm or M.S. in Pharmacology or a closely related discipline, with 1-2 years of research experience in academic or industrial R&D
Hands-on experience with small animal handling, multi-route dosing, dissection, tissue harvesting, and ELISA/qPCR/Western Blot
Deep understanding of pharmacology and in vivo compound testing in disease models
Strong organisational skills, attention to detail, and clear scientific communication
Scientific curiosity, strong work ethic, and a can-do attitude
We hire for trajectory, not just credentials. If you meet most of the above and care deeply about this problem, we want to hear from you
ABOUT ENVEDA
We're a clinical-stage, AI-enabled biotech discovering medicines four times faster than the industry standard.
We recently raised $150M in a Series D, reached unicorn status, and advanced our first drug into Phase 2 trials. Forbes named us one of America's Best Startup Employers. Newsweek recognized us as a Top 100 Most Loved Workplace.
We're building something rare and we're just getting started.